Status:
COMPLETED
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Lead Sponsor:
Laboratoires Thea
Conditions:
Ocular Hypertension
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
Eligibility Criteria
Inclusion
- Informed consent signed and dated.
- Both eyes with diagnosed open-angle glaucoma or ocular hypertension
Exclusion
- History of trauma, infection, clinically significant inflammation within the 3 previous months.
- Uncontrolled diabetic patient.
- Pregnancy or breast feeding.
Key Trial Info
Start Date :
November 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2021
Estimated Enrollment :
485 Patients enrolled
Trial Details
Trial ID
NCT03825380
Start Date
November 23 2018
End Date
February 24 2021
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital
Tallinn, Estonia